Comparative Pharmacology
Head-to-head clinical analysis: DOXYCYCLINE HYCLATE versus MONODOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCYCLINE HYCLATE versus MONODOX.
DOXYCYCLINE HYCLATE vs MONODOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline hyclate is a bacteriostatic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-angiogenic properties.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily. For severe infections or certain indications, 100 mg every 12 hours.
100 mg orally or IV every 12 hours on day 1, then 100 mg orally or IV every 24 hours; for severe infections, 100 mg every 12 hours.
None Documented
None Documented
18-24 hours in patients with normal renal function; may increase to 24-48 hours in renal impairment; clinical context: allows once- or twice-daily dosing.
Terminal elimination half-life: 14-22 hours (mean ~18 hours) in adults; prolonged up to 24-48 hours in renal impairment; no dose adjustment in mild-moderate renal impairment but caution in severe (CrCl <30 mL/min).
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-30% eliminated in feces via biliary secretion and nonbiliary routes; the remainder is metabolized. Enterohepatic circulation contributes to prolonged half-life.
Renal: ~40% (glomerular filtration, tubular secretion); biliary: ~20-60% (enterohepatic circulation); fecal: ~30% (unabsorbed or excreted in bile).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic